Jay Bradner, head of Novartis’ drug discovery, talks to pharmaphorum about the firm’s drive to transform itself into 'a medicine and data science company'.
Cutting-edge technologies are increasingly improving pharma’s R&D processes, which will reduce costs and, in turn, benefit patients, says Gunjan Bhardwaj.
In another example of the pharma industry embracing generative artificial intelligence (genAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio